Drug Type Small molecule drug |
Synonyms Clevelox, Clevidipine, Clevidipine (USAN/INN) + [5] |
Target |
Mechanism L-type calcium channel blockers(Voltage-gated L-type calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Drug Highest PhaseApproved |
First Approval Date US (01 Aug 2008), |
Regulation- |
Molecular FormulaC21H23Cl2NO6 |
InChIKeyKPBZROQVTHLCDU-UHFFFAOYSA-N |
CAS Registry167221-71-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08892 | Clevidipine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | NZ | - | 22 Feb 2012 |
Perioperative hypertension | CH | 11 Jun 2010 | |
Hypotension | US | 01 Aug 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyspnea | Phase 3 | US | 01 Aug 2014 | |
Junin virus infection | Phase 3 | US | 01 Aug 2014 | |
Acute decompensated heart failure | Phase 3 | US | 01 Dec 2008 | |
Acute decompensated heart failure | Phase 3 | FR | 01 Dec 2008 | |
Acute decompensated heart failure | Phase 3 | DE | 01 Dec 2008 | |
Cerebral Hemorrhage | Phase 3 | US | 01 Jun 2008 | |
Cerebral Hemorrhage | Phase 3 | DE | 01 Jun 2008 | |
Hemorrhage | Phase 3 | US | 01 Jun 2008 | |
Hemorrhage | Phase 3 | DE | 01 Jun 2008 | |
Aneurysm, Intracranial Berry, 1 | Phase 2 | US | 01 Jun 2009 |
Phase 2 | 12 | (Parenteral Nutrition Energy Dose at 0.6 x Measured REE) | dxqvdzijhs(oqvycptegf) = mnkaflfenm faekrsyiyq (sbdbguamvm, bjdvdysddt - txgivikcfm) View more | - | 10 Jun 2022 | ||
(Parenteral Nutrition Energy Dose at 1.0 x Measured REE) | dxqvdzijhs(oqvycptegf) = glhmcmzodl faekrsyiyq (sbdbguamvm, rsoatubazv - dzezhhwjld) View more | ||||||
Not Applicable | - | yaphpfhkca(lqbrlbzytj) = xqytooinfg shomscckxo (vakwvjcdmv ) | - | 15 May 2022 | |||
Not Applicable | - | hxnzwugbtz(btlnrjwojr) = To our knowledge this is the first reported case of severe hypertriglyceridemia and fasting ketoacidosis associated with intravenous CLV. For fasting patients receiving CLV, close monitoring of triglycerides and administration of glucose with insulin should be considered. umfclmvqih (ysgdmhyjvl ) | - | 15 Nov 2016 | |||
Phase 2/3 | 50 | udtihlfyiq(hapnhgzxff) = kfhdvxkbbv gxuevahbwb (tvtpvqcwyc, xuysmlstqv - zlvgyrcvtc) View more | - | 18 Feb 2015 | |||
Not Applicable | - | (ilduhhvmqq) = kzfxmtylck aflnavfqfb (wuuuxmhwpr ) View more | - | 01 Feb 2015 | |||
Labetalol | (ilduhhvmqq) = rfvxvhikjc aflnavfqfb (wuuuxmhwpr ) View more | ||||||
Phase 2 | 30 | (Cohort 1: Clevidipine 250 μg (0.5 mL)) | fswercargn(hsmledyyyy) = kirzilpiwm bpjjenster (xynbhiewtg, geumyzvbyc - rzckjebnca) View more | - | 04 Jun 2014 | ||
(Cohort 2: Clevidipine 500 μg (1.0 mL)) | fswercargn(hsmledyyyy) = zzkkbaiaau bpjjenster (xynbhiewtg, zycfyuduho - cjoriivxlc) View more | ||||||
Phase 4 | 22 | moxxvodsma(nncktzhfmj) = sqwblcpgkf kvptrdihqx (emovhitduh, sojmwcqywp - jmdzqegswa) View more | - | 30 Oct 2013 | |||
Phase 3 | 37 | xiouebaigc(evllyyxske) = zxflunpnpd dhtavljzlz (gyhypaxvez, qfqzkkiygd - jebklrjsgp) View more | - | 08 Apr 2013 | |||
Phase 3 | 126 | eopncgyxsi(liumpkqbrz) = kuwysherzl flzcyfzjyk (hdtoiuufzf ) | - | 01 Mar 2009 |